Today’s AI Top Pick: ALKT
10/2/2026 · Contrarian screen · a free sample of K3vl4r’s AI-curated picks.
AI-ranked from a screened shortlist, with entry strategy, targets, and risks.
View the live ALKT price forecast →
Alkami Technology (ALKT) is the best dip-buy right now because it uniquely combines a deep, exhausted drawdown with genuine fundamental quality and clean multi-timeframe alignment. The stock fell -26.29% over the last 14 days with a bullish probability of 1.0, and it sits at a favorable position within its 21-bar range: 6.43% on the 4h, 9.38% on the 1d, and 3.49% on the 1wk — all near the lower portion of the range, meaning it is NOT chasing a top and has room to bounce rather than making fresh lows. Critically, the forecast turns up across every horizon: fc_long_pct of 50.16% on the 1wk, 32.34% on the 4h, and 32.18% on the 1d all point to recovery, and the 14-day drawdown (-32.08% from the 21-bar high on the weekly) is already well past its low — this looks like exhausted selling, not a broken trend. Unlike most names in this pool, ALKT carries a real fundamentals block with a top-tier fundamental_score of 5.00. It trades at a forward P/E of just 12.96 against a PEG of only 0.34 — deeply cheap for a company growing sales 27.05% year-over-year, with a 47.5% analyst target upside and a strong 1.89 recommendation (near 'Strong Buy'). The 1d forecast magnitude of 36.59% mid-horizon is among the strongest in the entire candidate set. This is a $1.5B company with 74.7% institutional ownership and only 10.96% short float — no dilution overhang, no crowded short squeeze risk. The news flow is a clear tailwind, not a landmine: on 2026-10-01 ALKT 'Rejects Sale Push and Reaffirms 2026 Outlook,' signaling management confidence and removing takeover uncertainty, while a Gate City Bank deal validates its platform demand. The entry is ideal TODAY because the multi-timeframe lows have already formed (no waiting for a fresh capitulation), the forecast is already turning up on all horizons, and the fundamental floor (cheap forward earnings + high growth) gives this a real value anchor that most speculative biotechs and micro-caps in the pool lack. Waiting risks missing the bounce given the weekly fc_long of +50%.
- ROE of -12.77% and negative operating margin (-7.08%) / profit margin (-9.21%) show the company is still not profitable, capping how deep the value floor is
- 14-day drawdown of -26.29% could extend if broader tech/risk-off selling resumes; the weekly dd_from_21bar_high of -32.08% is already severe
- RSI at 28.02 is oversold but not deeply enough to guarantee an immediate bounce — could drift lower before recovering
- Bullish probability of 1.0 is model-imposed and uniform across the entire pool, so it provides no differentiating edge — the thesis rests on fundamentals + TFS, not the probability metric
- Small-cap tech liquidity risk at $1.5B market cap could widen spreads during the entry window
| # | Symbol | Verdict | Score | Read |
|---|---|---|---|---|
| 1 | ALKT | BUY NOW | 9.5 | Deep exhausted drawdown (-26.29%) with top fundamental_score (5.00), cheap forward P/E 12.96, and clean all-timeframe bullish forecast — best risk/reward dip-buy. |
| 2 | NEOV | BUY PULLBACK | 8.6 | Strong fundamentals (score 4.25, sales +58% YoY) and 1d fc_long +28.77%, but wait for a cleaner entry as 1wk fc is negative (-1.40%). |
| 3 | NPWR | BUY NOW | 8.3 | Clean TFS alignment with Outperform catalyst and huge 1d fc_long (+130%), but no earnings/margins to anchor value. |
| 4 | LUCD | BUY PULLBACK | 8.1 | Positive coding pathway news and 1d fc_long +83.98%, but deeply negative margins (-1193%) and high debtEq 2.28 add risk. |
| 5 | TPB | BUY PULLBACK | 7.9 | Profitable (profitMargin 8.78%, ROE 13.74%) with 1d fc_long +69.71%, but CEO resignation on 10-01 is a near-term landmine. |
| 6 | OXBR | BUY PULLBACK | 7.8 | Short interest fell 50% (bullish) and 1wk fc_long +18.83%, but tiny $9.2M cap and fwdPe unavailable limit conviction. |
| 7 | NXTC | BUY PULLBACK | 7.6 | Highest fundamental_score among biotechs (4.0) with 1wk fc_long +115.62%, but 1d fc_long +62% comes after a brutal -41% drawdown — wait for stabilization. |
| 8 | CABA | BUY PULLBACK | 7.4 | Oversold (RSI 25.88) with 1d fc_long +12.38%, but 1wk fc is deeply negative (-24.75%) and short float 25% invites volatility. |
| 9 | TVRD | BUY PULLBACK | 7.3 | Positive preclinical STAT3 data is a real catalyst, but 1wk fc_long -55.86% shows the weekly trend is still broken. |
| 10 | TARA | BUY PULLBACK | 7.1 | RSI 20.14 deeply oversold with 1d fc_long +60%, but negative epsNextY (-17.82) and 1wk fc_long +44% still unproven. |
| 11 | BTDR | BUY PULLBACK | 6.9 | Strong AI/cloud catalysts and sales +127% YoY, but 1d fc is negative (-6.28%) and short float 35% is a squeeze risk both ways. |
| 12 | OCUL | BUY PULLBACK | 6.7 | Needham reaffirms Buy $18 target, but a '3 Reasons to Avoid OCUL' headline on 10-01 is a near-term headwind and fc_long only +15.51%. |
| 13 | LRMR | WAIT | 6.5 | New COO catalyst and 1d fc_long +21.99%, but 1d fc_short +12.92% and no margins make the setup less clean. |
| 14 | NBP | WAIT | 6.3 | Oversold (RSI 25.14) but only 4h TFS available and insider selling of 107,978 shares is a caution. |
| 15 | GPCR | WAIT | 6.1 | Fresh obesity trial backing is positive, but shares down 6.1% on 10-01 and 1wk fc_long -5.87% shows weekly weakness. |
| 16 | XTIA | BUY PULLBACK | 5.9 | Explosive sales +1437% YoY and 1d fc_long +111.55%, but negative margins (-171%) and tiny $29.6M cap are high-risk. |
| 17 | RILY | BUY PULLBACK | 5.7 | Sangoma acquisition catalyst with profitMargin 30.72%, but 1wk fc_long +26.18% and debtEq 9.31 add leverage risk. |
| 18 | ONT | WAIT | 5.5 | 1d fc_long +53.57% and fwdPe 61.8, but negative profitMargin -1.44% and low 2.14 recommendation limit appeal. |
| 19 | WALD | WAIT | 5.2 | 1d fc_long +86.68% is strong, but H1 EPS miss, delist filing, and -100% profitMargin are serious landmines. |
| 20 | SST | WAIT | 5.0 | MapQuest user growth is positive and 1d fc_long +43.30%, but negative margins (-50%) and 1wk fc_short -77% show trend fragility. |
| 21 | CISO | AVOID | 4.8 | 1d fc_long +45% but near_term_bullish 0.0 and negative fc_short -5.61% on 1d signal caution — wait for confirmation. |
| 22 | CCM | AVOID | 4.6 | 1d fc_long +63.38% but recom 5 (Sell), negative targetUpside -59.2%, and profitMargin -20% make it a clear avoid. |
| 23 | BNAI | WAIT | 4.4 | 1d fc_long +3.66% is weak and $1.05M offering + $8.50 dilution on 09-22 is a landmine despite +707% sales growth. |
| 24 | AIRS | WAIT | 4.2 | 1d fc_long +91.69% is strong but AirSculpt weakness extends into Q3 and negative fc_mid +120% is unproven. |
| 25 | RCKT | WAIT | 4.0 | FDA alignment on heart trial is positive but recom 2.29 (Hold) and fc_long only +67.7% on 1wk limit conviction. |
| 26 | MTEK | WAIT | 3.8 | Record $10M order catalyst and 1d fc_long +83.94%, but no fwdPe, negative margins, and tiny $7.8M cap are high-risk. |
| 27 | SPPL | WAIT | 3.6 | Short interest fell 71% (bullish) and 1d fc_long +59.11%, but negative margins (-71%) and 1wk fc_short -57.67% show fragility. |
| 28 | RIME | AVOID | 3.4 | New CEO catalyst but 1wk fc_short -100%, negative fc_mid +292% unproven, and fundamental_score 0 make it a low-conviction avoid. |
| 29 | WMTX-USD | AVOID | 3.2 | Crypto with no fundamentals block; 1wk fc_long +486.77% is huge but near_term_bullish only 0.2 and -58% drawdown signals broken trend. |
Get AI top picks & forecasts on any stock
K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord